Biohaven Pharmaceutical (NYSE:BHVN) reported quarterly losses of $(1.75) per share. This is a 8.38 percent increase over losses of $(1.91) per share from the same period last year.
Cathie Wood Harps On Deflation Risk After Fed’s Powell Tones Down Inflation Commentary — Says These Investment Bets Will Be ‘Biggest Beneficiaries’
Fund manager Cathie Wood reiterated her view that the deflationary trend was playing out and handed out investment advice for such an environment.
